TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia

Ibrutinib may revert the T-helper (Th)2 polarization observed in chronic lymphocytic leukemia (CLL) by targeting the IL-2-inducible kinase, that shows a significant homology with the Bruton tyrosine kinase. In the front-line GIMEMA LLC1114 trial (ibrutinib+rituximab for 6 months, followed by ibrutin...

詳細記述

保存先:
書誌詳細
出版年:Front Oncol
主要な著者: Puzzolo, Maria Cristina, Del Giudice, Ilaria, Peragine, Nadia, Mariglia, Paola, De Propris, Maria Stefania, Cappelli, Luca Vincenzo, Trentin, Livio, Reda, Gianluigi, Cuneo, Antonio, Molica, Stefano, Piciocchi, Alfonso, Arena, Valentina, Mauro, Francesca Romana, Guarini, Anna, Foà, Robin
フォーマット: Artigo
言語:Inglês
出版事項: Frontiers Media S.A. 2021
主題:
Oncology
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8082026/
https://ncbi.nlm.nih.gov/pubmed/33937038
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.637186
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料